Background: Nitrous oxide (N 2 O) has been used in clinical and recreational settings for over 150 years. Through inactivation of the Vitamin B12 dependent enzyme, methionine synthase, N 2 O can lead to the development of peripheral neuropathy. This study sought to determine the relationship between the exposure and risk of neurological symptoms in the largest ever sample of users. Design: Data are drawn from the Global Drug Survey (GDS) over three consecutive years (2014)(2015)(2016). The Global Drug Survey is an online, crosssectional survey of substance use, translated into multiple languages. Participants: Respondents to the Global Drug Survey who provided details on N 2 O use and the experience of paraesthesia in the previous 12 months. Measurements: Questions relating to N 2 O use, peripheral neuropathy, age and gender were explored among last year's users. Findings: Of 241,566 respondents, 41,181 (17.0%) indicated that they had ever used nitrous oxide; of these, 42.1% had used in the last 12 months. For the final model, data from 16,124 participants who had used N 2 O in the last 12 months and had provided responses on age, dose, gender and paraesthesia were used. Of these, the number of respondents reporting persistent numbness/tingling (paraesthesia) in their hands or feet was 537 (3.3%). Although the risk was very low among infrequent users, there was a strong dose-response relationship. For people indicating one or two doses per session, the probability of reporting paraesthesia was approximately 0.018 by comparison; for people indicating 100 doses per session the probability was approximately 0.085. The association, between dose and paraesthesia was influenced by gender and age. Conclusion: While infrequent, episodic users are not at risk, a minority of heavy users are at dose-dependent risk of developing serious neurological consequences. Better education and raised awareness of early symptoms are required.
Introduction
Nitrous oxide (N 2 O, laughing gas) is a colourless, odourless gas that has a long history of use, both in clinical settings as an anaesthetic and analgesic agent (Brown and Sneyd, 2016) and within recreational settings (Kaar et al., 2016; van Amsterdam et al., 2015) . First popularised by Sir Humphry Davy in Victorian England (Davy, 1800) , the inhalation of nitrous oxide produces an extremely short-lived but intense euphoria with feelings of dissociation and mild changes in perception of body image, distinct from other inhalants and being described as more pleasant and psychedelic (Beckman et al., 2006) . The short-lived nature of the effects and the return to normal functioning within a few minutes make it a desirable substance for those seeking an intoxicating effect. It is also often used in the context of poly-drug use as it can enhance the effects of other drugs (Kaar et al., 2016) .
Although use for intoxicating purposes is banned in some countries, its widespread use within the food industry as a foaming agent (E942) and bacteriostatic (Home Office, 2014) makes its control almost impossible (Randhawa and Bodenham, 2016) . It is also used as fuel booster in car engines (Zuck et al., 2012) . Currently, most nitrous oxide that is consumed for recreational purposes is diverted from products created for the food industry. It is sold in small aluminium canisters, sometimes known as 'bulbs ', 'whippets' or 'nangs'; these are designed to be used in whipped cream dispensers, though they can be used in conjunction with a small metal container known as a 'cracker' which allows the gas canister to be punctured, with the gas dispelled into a balloon from which it is inhaled (Randhawa and Bodenham, 2016) . These can be purchased in supermarkets or online, with home delivery being offered in some countries. Nitrous oxide is cheap, with the cost for a single canister varying between 50 p and £2. At festivals, a single balloon filled with nitrous oxide can cost £5.
Nitrous oxide's psychoactive and anaesthetic effects are thought to be mediated through N-methyl-D-aspartate antagonism, decreasing excitatory neurotransmission throughout the central nervous system by non-competitive glutamate inhibition (Jevtovic-Todorovic et al., 1998) . Nitrous oxide also acts as a partial mu, kappa and delta opioid receptor agonist modulating dopamine activity within the nucleus accumbens, which may in part, be responsible for its analgesic effect (Gillman and Lichtigfeld, 1998) .
Although compared with other drugs nitrous oxide is remarkably safe; acute harms are seen following the recreational use of nitrous oxide including falls, freezing of the lips, accidental injury, confusion, hallucinations (Kaar et al., 2016) and pneumothorax (Garbaz et al., 2007) . Vomiting and aspiration among those with reduced levels of consciousness can also be seen (Randhawa and Bodenham, 2016) . Fatalities are very rare; most fatalities are commonly reported following accidental asphyxiation due to nitrous oxide's ability to displace oxygen in a closed space (in clinical practice nitrous oxide is combined with oxygen to minimise hypoxia) (Ghodse et al., 2012; Wagner et al., 1992) . Resultant hypoxaemia can precipitate seizures and arrhythmias in those with pre-existing epilepsy or cardiovascular disease. Between 2006 and 2012, 17 deaths were reported in the UK due to nitrous oxide (Wolfson, 2015) . Underlying much of its chronic clinical toxicity is nitrous oxide's interaction with vitamin B12, transforming the active monovalent form of B12 by irreversible oxidation into the inactive bivalent form (Banks et al., 1968; Chanarin, 1982) . Vitamin B12 is a co-factor for the conversion of L-methylmalonyl coenzyme A into succinyl coenzyme A (Krautler, 2012) and for methionine synthase, which produces methionine by the methylation of homocysteine. The latter is required for DNA synthesis and the maintenance of the myelin sheath, with B12 deficiency causing demyelination within the central and peripheral nervous systems. Nitrous oxide-induced oxidation of vitamin B12 thus results in the impairment of methylation reactions and DNA synthesis and an accumulation of homocysteine (Flippo and Holder, 1993) . Other mechanisms for the observed neurological sequelae have been proposed, including interference with the cytokine system (Hathout and El-Saden, 2011) . Complications attributable to interference with vitamin B12 metabolism (Stockton et al., 2017) have been reported, including bone marrow suppression with megaloblastic anaemia (Chiang et al., 2013) , agranulocytosis (Peck et al., 2008) myeloneuropathy (Layzer et al., 1978) , subacute combined degeneration of the spinal cord (Chaugny et al., 2014) and reversible psychosis (Sethi et al., 2006) .
Data on recreational nitrous oxide use in general population studies of drug use are often limited as many countries classify nitrous oxide under the category of volatile solvents or inhalants (e.g. Australia (Australian Institute of Health and Welfare, 2017)) or where specific questions are asked about recreational nitrous use; these questions are often limited to prevalence (e.g. New Zealand (Ministry of Health, 2010) (Wu and Ringwalt, 2006) . However, the NSDUH does not capture prevalence data on recent (last year) use of nitrous oxide. By comparison, the 2017/2018 Crime Survey for England and Wales found a prevalence last year of 2.3% in those aged 16-59; this prevalence was over three times higher, at 8.8%, for people in the 16-24 year age group (Home Office, 2018) .
In previous work (Kaar et al., 2016) , the Global Drug Survey (GDS) had described current patterns of recreational nitrous oxide use and the 12-month incidence of acute adverse events. We reported that 4.2% of last year's users reported persistent numbness in their limbs following use. In this current paper, we build on this research and use the biggest sample of nitrous oxide users ever recruited to better define the neurological symptoms and explore any dose-response relationship between exposure to nitrous oxide, age and gender and symptoms consistent with peripheral neuropathy (persistent numbness). We hypothesise that there is a positive significant relationship between the 'per session' dose rate of nitrous oxide and the frequency of use and the reporting of symptoms consistent with B12-related peripheral neuropathy. Further, we explore whether differences exist that relate to a person's gender and age in the dose-response relationship of nitrous oxide and persistent numbness.
Study design and sample
The GDS runs the world's largest online drug survey (www. globaldrugsurvey.com). It is a cross-sectional, self-completed and anonymous survey which has been conducted annually since 2012. GDS is translated into multiple languages and is promoted through partnerships with media organisations, harm reduction organisations and social media networks. Participants engage the survey on a self-nominating basis; as such, responses are not nationally representative and data are drawn from a non-representative sample. For more information, see the paper by Barratt et al. (2017) , which provides extensive detail around the GDS methodology, including the history of GDS, orientation towards specific groups (i.e. drug users), survey design and recruitment approaches. Ethical approval was obtained from the King's College London Psychiatry, Nursing and Midwifery Research Ethics Subcommittee (PNM RESC: see PNM 141/02, PNM 14/15-18) and University of Queensland (Reference: 2017001452 /11671/001).
For the current analysis, we combined identical questions exploring nitrous oxide use and associated health harms and socio-demographic variables collected as part of GDS2014, GDS2015 and GDS2016, conducted over November and December for each year, 2013-2015 respectively. Data preparation and cleaning is described elsewhere (Barratt et al., 2017) . Only cases where participants reported using nitrous oxide in the last 12 months were retained for analysis. As a conservative measure to ensure that data across the three years contains only unique cases, where participants reported that they had participated in the GDS in a previous year, these data were removed.
Measures
Demographic data used for analysis include gender (male and female only) and age (continuous). The GDS annual survey starts with questions on basic demographics, followed by an extensive drug screen (100+ drugs) where participants indicate whether they had ever used, used in the last 12 months or used in the last month. Participants who indicated nitrous oxide use during the last 12 months were then offered the opportunity to complete a more in-depth section exploring their patterns of use of nitrous oxide, including the context of use, source of substance, route of administration, frequency of use and quantity used. People who had not used nitrous oxide in the last 12 months were excluded since we were concerned that recall beyond 12 months would be of limited value and that our focus on current neurological symptoms required a focus on recent users. Finally, questions are asked regarding adverse effects and the experience of previously unexperienced but persistent neurological symptoms.
To estimate the dose consumed on a day of use, we used the same approach adopted in our previous study (Kaar et al., 2016) , asking 'how many hits (inhales) would you have on a day that you use?' (while not explicitly asked we determine a 'hit' to represent one bulb of nitrous oxide). One 8 g bulb of nitrous oxide, pressurised at 7-9 bars, contains approximately 10 mL of nitrous oxide in liquid form (Garland et al., 2009; van Amsterdam et al., 2015) and is sufficient to inflate one large-size 12-inch latex party balloon (Butzkueven and King, 2000) . This is the most widely adopted method of administering nitrous oxide within recreational settings.
To assess the presence of peripheral neuropathy, respondents answering the GDS 2014 survey were asked whether they had ever experienced 'persistent numbness/tingling in your arms/legs (lasting days and weeks after using)?' Response options were: 'Yes (in last 12 months)', 'Yes (not in last 12 months) ' and 'No'. In GDS 2015 and GDS 2016 , to better capture peripheral neuropathy, respondents were asked two separate questions: 'numbness/ tingling around the face or mouth that has persisted for at least 2 weeks following your last use of nitrous and that you had not experienced before you started using nitrous?' and 'numbness/ tingling in the hands or feet that has persisted for at least 2 weeks following your last use of nitrous and that you had not experienced before you started using nitrous?'. Response options were: 'Yes (within last 12 months)', 'Yes (not within last 12 months)' and 'No'. To maintain consistency across the three years of data, a binary response proxy (yes/no) for recent peripheral neuropathy was constructed from the GDS 2014 question and the GDS 2015 and GDS 2016 question relating to numbness/tingling in the hands or feet. If the respondent indicated 'Yes (within the last 12 months)', this was coded as 'Yes (experienced paraesthesia)', or if the respondent indicated 'No', this was coded as 'No (did not experience paraesthesia)'. Participants who indicated 'Yes (not within the last 12 months)' were excluded from analysis.
Analyses
Both descriptive and inferential analyses were undertaken using Stata 15.0 (StataCorp, 2017) . When presenting descriptive statistics, to account for missing data, valid percentages are reported rather than absolute values. To examine gender differences in the consumption practices and risks of neurological harm, we employ chi-squared and Fisher's exact tests. Finally, we used multivariable logistic regression models to examine whether specific demographics (age and gender) are associated with a greater propensity for participants to report neurological harms. For models where age is included as a covariate, both the linear form and the quadratic form of age are examined.
The following generalised logistic regression model, where Only the best fit model, based on AIC, BIC and likelihood ratio test statistics is presented. As the method of recruitment was purposive, confidence intervals are provided to illustrate the range of values associated with the sample's standard error and to compare differences in point estimates. All statistical tests were two tailed and the significance level was set at 0.05. The predicted probabilities presented in the dose-response figures were constructed using Stata's post-estimation 'margins' command. The range of values for dose-response were estimated for the natural log of dose (ranging from 0 to 4.6 in steps of 0.1).
Results
Across the three years of data, there were 241,566 respondents, in which there were over 80,000 respondents in 2015 and 2016 (see Table 1 ).
In total 17,325 respondents indicated using nitrous oxide in the last 12 months. The mode of administration of N 2 O for the majority of respondents was via balloons, followed by whipped-cream dispensers and across the three years the main preparation method used was bulbs (small metal canisters). Of the 17,325 respondents 812 did not indicate how much nitrous oxide they used per session. For the 16,513 respondents indicating a dose per session, the median number of doses was around 5 (see Table 1 ) but this ranged from one dose (n=1344; 8.1%) to 100 or more doses (n=130; 0.8%). Of these 16,513 respondents, a further 274 did not provide a valid response to experiencing paraesthesia.
The following analysis is based on the 16,239 respondents who indicated using nitrous oxide in the last 12 months, provided a per session dose-response and provided a valid answer to experiencing paraesthesia.
Fitting the base model (see Table 2 , Model 1) with the independent variable natural log of per session dose -ln(nitrous dose) suggests a significant relationship between dose and paraesthesia. That is, for every 10% increase in dose, there is a 3.5% increase in the likelihood of reporting paraesthesia. Figure 1 highlights the doseresponse curve between the number of doses per session and the predicted probability of reporting paraesthesia. For example, of the 1313 (8.1%) respondents reporting only one nitrous oxide dose in a session, the probability of reporting paraesthesia was 1.86% (95% confidence interval (CI): 1.52-2.19). By contrast, for respondents reporting 20 nitrous oxide doses in a session, the probability of reporting paraesthesia was 5.04% (95% CI: 4.44-5.65) and for respondents reporting 100 nitrous oxide doses in a session, the probability of reporting paraesthesia was 8.48% (95% CI: 6.58-10.4).
Of the 16,124 respondents, 11,184 (69.3%) were men. Including gender as a covariate in the fitted model (see Table 2 , Model 2), both as a main effect and as an interaction term with the dose, suggests that the dose-response curve relating to nitrous oxide use and reporting paraesthesia significantly differs for men and women. As depicted in Figure 2 , at low doses, eight doses per session or less, the predicted probability for reporting paraesthesia is significantly greater for men than for women. By 16 doses per session, the two curves intersect and following this the predicted probability of reporting paraesthesia is greater for women than for men. While the total number of respondents using 16 doses or more is considered sufficient to model the data up to 100 doses (men = 1311 (11.7%); women = 457 (9.3%)), it is important to note that respondents were more likely to round dosing responses to the nearest 5 or 10. For example, only 19 men and 16 women report using 16 doses in a session while 452 men and 165 women reported using 20 doses per session. Similarly, only four men and zero women reported using 49 doses in a session while 106 men and 37 women reported using 50 doses in a session. The overlap in the confidence intervals for 16 or more doses for men and women is most likely influenced by the insufficient power to detect differences related to these non-rounded dose levels (e.g. 16, 17, 29, 38 etc.) . However, the overall model (see Figure 2 ) does suggest a clear difference between men and women in the probability point-estimate for reporting paraesthesia as doses exceed 25 in a session. By 100 doses of nitrous oxide, the predicted probability for women reporting paraesthesia was 12.1% (95% CI: 7.16-17.0%) compared with men 7.2% (95% CI: 5.3-9.2%); the Wald test for statistical differences was (χ 2 1 =3.22; p=0.073).
Of the 16,239 respondents, the median age was 22 years (25th percentile: 19 years; 75th percentile: 25 years). Including age as a covariate in the fitted model (see Table 2 , Model 3), the best model was including age only as a main effect. This suggests that the main effects of age and dose per session significantly influence respondents reporting paraesthesia, but per session, there is no statistically significant interaction between the covariates. As depicted in Figure 3 , the younger the respondent, the more likely the respondent would report paraesthesia; similarly, the greater the dose per session, the greater the predicted probability of reporting paraesthesia. A respondent who was 40 years of age, reporting two doses per session had a predicted probability of approximately 1-2%; a 16-year-old, by comparison, having the same dose, would have a predicted probability of reporting paraesthesia of between 3% and 4%.
The Full Model (see Table 2 ) includes the significant covariates: gender (and the interaction term with nitrous dose) and age. Overall, for men, compared with women, the predicted probabilities for reporting paraesthesia are substantially lower as the nitrous oxide dose per session increases. Moreover, at younger ages, compared with women, men are more likely to report paraesthesia; however, the increased probability of reporting paraesthesia is lower for men compared with women as the nitrous oxide dose increases. Finally, for young men indicating up to 100 doses per session, the predicted probability of reporting paraesthesia is less than 10% by comparison; for young women using up to 100 doses per session the predicted probability of reporting paraesthesia is almost 16%.
Limitations
Consumption of nitrous oxide is based upon self-report and is subject to recall bias. None of the neurological symptoms or functional disturbances reported by users were confirmed by clinical examination and there is no supportive biochemistry to determine the levels of vitamin B12. However, our choice of clinical symptoms reflects the most common neurological presentations of those with B12 deficiency and would be easily recognisable by the person themselves. For example, in a study of 143 patients with B12 deficiency assessed by Healton et al. (1991) , almost three-quarters presented neurological symptoms, with isolated numbness or paraesthesia being present in one-third and gait abnormalities in 12%. Our choice of symptoms is also supported by those first reported by Layzer et al. (1978) , and more recently seen as presenting symptoms in cases associated with recreational nitrous oxide abuse, including uncomfortable tingling sensations in the feet and poor balance (Cheng et al., 2013) , hand numbness and difficulty with fine motor movements and gait ataxia (Stockton et al., 2017; Thompson et al., 2015) .
The limitations and utility of non-probability samples in exploring drug-related harms are addressed in previous work published by the group (Barratt et al., 2017) .
Discussion
This study represents the largest investigation of neurological symptoms among nitrous oxide users ever conducted, with over 16,000 recent consumers recruited for the study over three years. Our findings support our hypothesis that nitrous oxide causes peripheral neuropathy in a dose dependent manner among recreational users. We present a clear dose-response relationship that is 3.71; p = 0.024 2.28; p = 0.028 2.21; p = 0.038 1.80; p = 0.040 Linktest: _ hat 2 : (β; p-value) 0.42; p = 0.100 0.19; p = 0.213 0.18; p = 0.252 0.120; p = 0.357 Goodness-of-fit (df; χ 2 ; p-value) (10 groups) 6; 8.12; p = 0.230 8; 6.72; 0.567 8; 7.14; 0.5221 8; 16.99; 0.030 a Excluding 115 cases due to no valid gender answer. b LR test with (age 2 , age and interaction terms) vs. (age and interaction term) = LR χ 2 (2) = 2.45, p = 0.293; (age and interaction term) vs. (age and no interaction) = LR χ 2 (1) = 1.25; p = 0.264. Therefore, on parsimonious grounds, (age and no interaction) is the best model. both statistically significant and clinically relevant to a large number of users of this drug which is easily accessible around the world. While our findings also suggest that for the vast majority of consumers who use infrequently and at low levels, its use poses little or no risk; the potential neurological consequences for a minority of users warrant effective health promotion and raised awareness among users and clinicians. The greater vulnerability among women reflects the higher incidence of Vitamin B12 deficiency in women of reproductive age (Allen, 2009; Green et al., 2017) , and is perhaps related to diet. For example, that those adhering to vegetarian and vegan diets were more susceptible to nitrous oxide-induced neurological symptoms is consistent with the high rates of B12 deficiency in these populations due to suboptimal intake, with rates of 21-40% noted among adolescents (Allen, 2009 ) Nitrous oxide induced neuropathy was first reported nearly 40 years ago, among three habitual users who presented with a mainly sensory but disabling peripheral neuropathy with numbness that was 'radicular rather than purely distal' (Layzer et al., 1978) . Initial case reports of nitrous oxide-induced myeloneuropathy typically involved health care professionals who had easy access to nitrous oxide within their work environment, presented with clinical features comprising patchy tingling and paraesthesia in the hands and feet, weakness, loss of balance, difficulty with walking, impaired manual dexterity, poor balance and leg weakness (Brodsky et al., 1981; Jameson et al., 1999) . The first case report of polyneuropathy associated with the use of 'whippets' (slang term for nitrous oxide cartridges used in the catering industry) was made in 1978 (Sahenk et al., 1978) . Since that time, case series involving recreational users have been reported internationally, typically in the context of heavy chronic exposure (Cheng et al., 2013; Chiang et al., 2013; Nevins, 1980; Stockton et al., 2017; Thompson et al., 2015) .
B12 deficiency rarely presents with the classic triad of weakness, sore tongue and paraesthesia, and so the varied array of non-specific symptoms (including depression, irritability and personality change) can often lead to the diagnosis being overlooked or attributed to other conditions (Lindenbaum et al., 1988; Oh and Brown, 2003) . In otherwise healthy well-nourished individuals, a presentation of a peripheral neuropathy and functional loss should prompt direct enquiry about the recreational use of nitrous oxide. Imaging may be useful to assess for the presence of subacute combined degeneration of the spinal cord, typically showing abnormal hyper intensity of the dorsal columns (Stockton et al., 2017) . The neurological presentation may be diverse, however, with sensorimotor peripheral neuropathy occurring in the absence of clinical or imaging evidence of myelopathy (Thompson et al., 2015) .
Early diagnosis and prompt treatment are required to avoid disease progression and to increase the chance of full recovery, with response to treatment strongly related to the severity and duration of the condition before treatment (Healton et al., 1991; Ralapanawa et al., 2015) .
Although high dose oral vitamin B12 (1-2 mg/d) may be effective in reversing anaemia and neurological symptoms, high dose injection with loading doses and weekly supplements leads to swifter resolution of symptoms and should be considered in those presenting with more significant deficits (Langan and Goodbred, 2017) . Full neurological recovery is seen in about half of those with Vitamin B12 deficiency following treatment (Healton et al., 1991) . However, in those presenting late, even high dose therapy may leave individuals with persisting disability, including those associated with recreational abuse (Thompson et al., 2015) . Biochemical diagnosis relies upon a combination of tests, including serum B12, holotranscobalamin (both reduced) and methylmalonic acid levels (raised) (Green, 2017; Stabler, 2013) . Response and compliance should be determined through both clinical and biochemical measures, e.g. vitamin B12, homocysteine, and methylmalonic acid levels, two to three months after initiating treatment (Oh and Brown, 2003; Stabler, 2013) .
Nitrous oxide use is unlikely to diminish as a result of change in regulation or enforcement and governments committed to reducing drugs-related harm should focus on smart education, and not blunt and often ineffective regulation. The most effective response is likely to be targeted health promotion campaigns raising awareness of early neurological symptoms among heavy consumers and signposting the need for the cessation of use and urgent self-referral, should index symptoms be experienced. Clinicians across the field require a high index of suspicion and direct enquiry about the use of nitrous oxide to allow the early diagnosis and treatment of nitrous oxide-induced B12 deficiency.
